MarketLens
Sign Up

Has Alumis's Envudeucitinib Redefined Psoriasis Treatment

5 months ago
SHARE THIS ON:

Has Alumis's Envudeucitinib Redefined Psoriasis Treatment

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News3 weeks ago

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Vanda Pharmaceuticals' imsidolimab received European Commission Orphan Designation for generalized pustular psoriasis, the first EU orphan recognition for a GPP treatment, following EMA's positive opi...
Stock News1 months ago

Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates

Alumis Inc. (NASDAQ:ALMS) reported topline data from its ONWARD3 long-term extension study, showing its oral therapy envudeucitinib achieved leading skin clearance rates for patients with immune-media...
Stock News1 months ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer's oral drug restored skin pigmentation in two late-stage vitiligo trials, paving the way for regulatory submissions in the autoimmune skin disease.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

Generac, Amazon strike $2.4 billion long-term generator supply deal

Stock News2 hours ago

A Broad-Based Earnings Growth Picture as Revisions Stay Positive

Stock News2 hours ago

Why Intel Stock Jumped Today

Stock News2 hours ago

LARRY KUDLOW: Prosperity is as American as apple pie

Stock News2 hours ago

Diamondback Energy Inc (FANG) Stock Down 8.0% -- Now Undervalued? GF Score: 61/100